Kineta could receive more than $359 million as a result of the deal.
Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company.
Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta’s existing target therapy into a medicine that treats nerve pain.
“There is a tremendous unmet patient need to develop more effective, safer and nonaddictive therapies for the many people who suffer from chronic pain,” Kineta CEO Shawn Iadonato said in a statement Monday.
The Seattle company will be eligible to receive up to $359 million as part of the deal, in addition to an undisclosed upfront payment. It could also receive royalties on eventual sales of products that result from the deal.
Most Read Business Stories
- Amazon: Canceled New York jobs likely to go elsewhere; company will 'continue to evaluate' growth in Seattle
- Airbus's A380 failure ripples through its rivalry with Boeing in complex ways
- Record 7 million Americans are 3 months behind on car payments, a red flag for economy
- REI CEO Jerry Stritzke resigns, saying he failed to disclose a 'personal' relationship
- Delta's Seattle-based employees get $47 million in bonuses